2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/07/17Verastem to Present at 19th Annual BIO CEO & Investor Conference
BOSTON--(BUSINESS WIRE)--Feb. 7, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th at 9:00 a.m. ET at the Waldorf Astoria Hotel in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived ... 
Printer Friendly Version
01/26/17Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer
Phase 1/2 Study Expected to Enroll Approximately 100 Patients at up to 15 sites in the U.S. BOSTON--(BUSINESS WIRE)--Jan. 26, 2017-- Verastem, Inc., (NASDAQ:VSTM) today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanc... 
Printer Friendly Version
01/19/17Verastem Announces Executive Leadership Appointments and Changes
Hagop Youssoufian, MSc, MD Named Head of Hematology and Oncology Development; Greg I. Berk, MD to Transition to Senior Advisor and Member of Clinical and Scientific Advisory Board Lori Kunkel, MD and Edmund J. Pezalla, MD, MPH Appointed to Clinical and Scientific Advisory Board Michael Ferraresso to Join the Company as Vice President, Commercial Operations BOSTON--(BUSINESS WIRE)--Jan. 19, 2017-- Verastem, Inc. (NASDAQ: ... 
Printer Friendly Version